Back to top

Analyst Blog

The United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent application for the composition of BioLineRx Ltd.’s (BLRX) BL-5010. BL-5010 is being developed for the non-surgical removal of skin lesions.

The U.S. patent for BL-5010 is valid till 2022 from the date of issue. Meanwhile, the corresponding patents for BL-5010 in Europe and Israel have already been granted. BioLineRx also has a pending patent application for the candidate around the world. The pending patent application, if allowed, will be valid until 2033.

BL-5010 demonstrated encouraging results in a phase I/II study. In the phase I/II pilot study (n=60), BL-5010 was effective in 96.7% of the cases for removal of the target lesion within a month. Moreover, BL-5010 was well tolerated and no persistent irreversible adverse effect was noticed during the study. BioLineRx is also exploring potential partnership options.

BioLineRx now intends to initiate a pivotal CE-mark registration study on the final product, known as BL-5010P. The study is expected to begin by year end. The successful completion of the study will enable the company to apply for CE-mark registration of the candidate. BioLineRx expects the candidate to be approved in Europe by the end of next year. The company also has plans to expand the candidate’s label in additional therapeutic indications like actinic keratosis.

We note that BioLineRx has a worldwide exclusive license agreement with Innovative Pharmaceutical Concepts, Ltd. for BL-5010.

Apart from BL-5010, other interesting candidates in BioLineRx’ pipeline include BL-1040 for preventing pathological cardiac remodelling following a myocardial infarction (CE-Mark registration trial), BL-8040 for treating acute myeloid leukemia and other hematological cancer (phase II) and BL-7010 for celiac disease (expected to be in phase I/II by the end of 2013).

BioLineRx carries a Zacks Rank #3 (Hold). Stocks such as Endo Health Solutions Inc. (ENDP - Analyst Report), Isis Pharmaceuticals, Inc. (ISIS - Analyst Report) and Actelion Ltd. (ALIOF) currently look better positioned with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%